Novan (NOVN) Stock Price, News & Analysis

Company Overview

Novan, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is headquartered in Durham, North Carolina.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 7.19 million shs
• Average Volume: 602,421 shs
• Market Capitalization: $2.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NOVN Stock Analysis - Frequently Asked Questions

How were Novan's earnings last quarter?

Novan, Inc. (NASDAQ:NOVN) announced its quarterly earnings results on Monday, May, 15th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.32) by $0.22. The firm had revenue of $3.17 million for the quarter, compared to analyst estimates of $6.19 million. Novan had a negative net margin of 128.61% and a negative trailing twelve-month return on equity of 700.28%.
Read the conference call transcript.

When did Novan IPO?

Novan (NOVN) raised $46 million in an initial public offering on Wednesday, September 21st 2016. The company issued 3,800,000 shares at a price of $11.00-$13.00 per share. Piper Jaffray acted as the underwriter for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What other stocks do shareholders of Novan own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Novan investors own include Meta Platforms (META), Bionano Genomics (BNGO), Inovio Pharmaceuticals (INO), Tonix Pharmaceuticals (TNXP), NIO (NIO), Tesla (TSLA) and Zomedica (ZOM).

Company Calendar

• Last Earnings: 5/15/2023
• Today: 9/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:NOVN
• CIK: 1467154
• Web: www.novan.com
• Phone: (919) 485-8080
• Fax: 919-237-9212
• Employees: 90
• Year Founded: 2008

Profitability

• EPS (Trailing Twelve Months): ($1.32)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$31.31 million
• Net Margins: -128.61%
• Pretax Margin: -128.39%
• Return on Equity: -700.28%
• Return on Assets: -39.58%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.74
• Quick Ratio: 0.72

Sales & Book Value

• Annual Sales: $24.71 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.19 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 28,015,000
• Free Float: 27,651,000
• Market Cap: $2.64 million
• Optionable: Not Optionable
• Beta: -0.06